Our findings demonstrate the complexity of cancer care in custodial settings, identifying barriers and enablers to equitable ...

Olivia Munn is living with a new normal after undergoing a double mastectomy and entering medically induced menopause last ...

King Charles III on Tuesday makes his first official public appearance since being diagnosed with cancer, after doctors said ...

AstraZeneca and Daiichi Sankyo's Enhertu, a HER2-directed antibody drug conjugate (ADC), has demonstrated significant ...

Recommend PSMA radioligand therapy before chemotherapy for patients who (i) meet imaging criteria for PSMA radioligand ...

metastatic or recurrent biliary tract cancer (N=24). Findings showed an overall response rate (ORR) of 37.5% (95% CI, 18.8-59.4). Median duration of response and progression free survival were 9.4 ...

(UroToday.com) The 2024 Advanced Prostate Cancer Consensus Conference (APCCC) held in Lugano, Switzerland between April 25 th ...

The patients had sarcoma (n=7), melanoma (n=3), ovarian/peritoneal cancer (n=3), head and neck cancer (n=2), HER2-positive breast cancer (n=1), non-small cell lung cancer (n=1), anaplastic thyroid ...

New research in the April 2024 issue of Journal of the National Comprehensive Cancer Network showcases the feasibility of ...

November is Pancreatic Cancer Awareness Month, which makes this a good time to learn more about the risk factors for pancreatic cancer and what you can do to keep yourself safe. More than 64,000 ...

At a live virtual event, Edward S. Kim, MD, MBA, discussed the evolving landscape of biomarker testing before making ...

Positive high-level results from the DESTINY-Breast06 Phase III trial showed that ENHERTU® (fam-trastuzumab deruxtecan-nxki) demonstrated a statistically significant and clinically meaningful ...